Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans.

Eveline DelooseI DepoortereJ de HoonA Van HeckenO E DewitL S Vasist JohnsonM E BartonG E DukesTack Jan

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2017)

Considering its stimulating effect on the MMC and gastric emptying, camicinal is an attractive candidate for the treatment of gastroparesis and gastroesophageal reflux disease. This trial was registered at clinicaltrials.gov as NCT00562848.

Keyphrases

gastroesophageal reflux disease
study protocol
clinical trial
signaling pathway
phase ii
randomized controlled trial
combination therapy